Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356271 | 0.86 | AKR1C3 (0.52) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL18231508 | 0.84 | MAPT (0.56) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL3507981 | 0.84 | NPC1 (0.49) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL6671614 | 0.83 | CES2 (0.47) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL29039593 | 0.82 | CES2 (0.50) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL1547296 | 0.81 | KDM4E (0.47) | LMNAMAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL25460833 | 0.81 | NPC1 (0.47) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL8178552 | 0.80 | KDM4E (0.47) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL7680503 | 0.79 | PARP1 (0.45) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL3928629 | 0.79 | CNR2 (0.50) | CES2CES1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960368-B1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2311814-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7851626-B2 | 4,4,5,5, tetrasubstituted imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| EP-2130822-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| EP-1960368-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | DING QINGJIE | 2007-06-07 | — | — | US | disclosed |
| WO-2007063013-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | RPS4X, RPS4Y1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CES2 1520/4885CES1 746/4885NPC1 2015/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | CES2 3074/4885CES1 1632/4885NPC1 437/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | CES2 3033/4885CES1 1640/4885NPC1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.